Literature DB >> 23105613

Positive influence of Methotrexate-Hydroxychloroquine combination on the expression of GM-CSF receptor on neutrophils of synovial fluid in rheumatoid arthritis.

Ananth N Rao1, Beena V Shetty, D M Vasudevan.   

Abstract

Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) has been inducted as a mediator of inflammation in rheumatoid arthritis. Methotrexate combination therapy forms an important component of the treatment regimen in rheumatoid arthritis. The present study was undertaken to evaluate the influence of Methotrexate-Hydroxychloroquine (MTX-HCQ) combination and Sulfsalazine- Hydroxychloroquine (SSZ-HCQ) combination on the expression GM-CSFR in neutrophils isolated from synovial fluids. 15 cases of confirmed rheumatoid arthritis patients who presented at the hospital for surgical correction of joint deformities were selected for the study. Neutrophils isolated from the synovial fluids were used as the source of the receptor for quantitation on an enzyme immunoassay (EIA). The EIA was developed and standardized in our laboratory for quantification of the GM-CSF R. The findings are suggestive of the fact that the administration of MTX-HCQ combination has positive influence on the expression of the GM-CSF R on neutrophils as against SSZ-HCQ combination. The physiological basis of this increase needs further investigation.

Entities:  

Keywords:  GM-CSF receptor; Methotrexate; Rheumatoid arthritis; Synovial fluid

Year:  2006        PMID: 23105613      PMCID: PMC3453999          DOI: 10.1007/BF02912911

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  16 in total

Review 1.  Physiology of cytokine pathways in rheumatoid arthritis.

Authors:  W P Arend
Journal:  Arthritis Rheum       Date:  2001-02

Review 2.  Molecular physiology of granulocyte-macrophage colony-stimulating factor.

Authors:  J C Gasson
Journal:  Blood       Date:  1991-03-15       Impact factor: 22.113

3.  Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.

Authors:  M Boers; A C Verhoeven; H M Markusse; M A van de Laar; R Westhovens; J C van Denderen; D van Zeben; B A Dijkmans; A J Peeters; P Jacobs; H R van den Brink; H J Schouten; D M van der Heijde; A Boonen; S van der Linden
Journal:  Lancet       Date:  1997-08-02       Impact factor: 79.321

4.  Characterization of the human granulocyte-macrophage colony-stimulating factor receptor.

Authors:  J DiPersio; P Billing; S Kaufman; P Eghtesady; R E Williams; J C Gasson
Journal:  J Biol Chem       Date:  1988-02-05       Impact factor: 5.157

5.  Expression of GM-CSF receptor in rheumatoid arthritis.

Authors:  M Field; L Clinton
Journal:  Lancet       Date:  1993-11-13       Impact factor: 79.321

6.  Gene amplification and drug resistance.

Authors:  R T Schimke
Journal:  Sci Am       Date:  1980-11       Impact factor: 2.142

7.  Treatment of early rheumatoid arthritis with minocycline or placebo: results of a randomized, double-blind, placebo-controlled trial.

Authors:  J R O'Dell; C E Haire; W Palmer; W Drymalski; S Wees; K Blakely; M Churchill; P J Eckhoff; A Weaver; D Doud; N Erikson; F Dietz; R Olson; P Maloley; L W Klassen; G F Moore
Journal:  Arthritis Rheum       Date:  1997-05

8.  Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications.

Authors:  J R O'Dell; C E Haire; N Erikson; W Drymalski; W Palmer; P J Eckhoff; V Garwood; P Maloley; L W Klassen; S Wees; H Klein; G F Moore
Journal:  N Engl J Med       Date:  1996-05-16       Impact factor: 91.245

9.  Cytokines in chronic inflammatory arthritis. II. Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions.

Authors:  W D Xu; G S Firestein; R Taetle; K Kaushansky; N J Zvaifler
Journal:  J Clin Invest       Date:  1989-03       Impact factor: 14.808

10.  Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients.

Authors:  G S Alarcón; I C Tracy; G M Strand; K Singh; M Macaluso
Journal:  Ann Rheum Dis       Date:  1995-09       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.